Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -17.40% is 58% above its 5-year average of -41.17%, near the high end of its 5-year range (-68.24%–-17.40%).
65.10% above its 12-month average of -49.85%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.33%.
RETURN ON ASSETS (ROA)
-17.40%
RETURN ON ASSETS (ROA) AVG TTM
-49.85%
RETURN ON ASSETS (ROA) AVG 3Y
-45.66%
RETURN ON ASSETS (ROA) AVG 5Y
-41.17%
RETURN ON ASSETS (ROA) AVG 10Y
-32.84%
RETURN ON ASSETS (ROA) AVG 15Y
-48.51%
RETURN ON ASSETS (ROA) AVG 20Y
-45.27%
CURRENT VS TTM AVG
+65.10%
CURRENT VS 3Y AVG
+61.89%
CURRENT VS 5Y AVG
+57.73%
CURRENT VS 10Y AVG
+47.01%
CURRENT VS 15Y AVG
+64.13%
CURRENT VS 20Y AVG
+61.57%
SECTOR MEDIAN · HEALTHCARE
-23.27%
median of 386 covered companies
CURRENT VS SECTOR MEDIAN
+25.24%
vs the sector median at left
Altimmune, Inc.
Market Cap
$519.25M
Return on Assets (ROA)
-17.40%
TTM Avg
-49.85%
3Y Avg
-45.66%
5Y Avg
-41.17%
Market Cap
$517.79M
Return on Assets (ROA)
-89.18%
TTM Avg
-100.15%
3Y Avg
-92.96%
5Y Avg
-79.13%
Market Cap
$517.73M
Return on Assets (ROA)
-30.08%
TTM Avg
-46.42%
3Y Avg
-46.30%
5Y Avg
-37.15%
Market Cap
$491.93M
Return on Assets (ROA)
-13.84%
TTM Avg
-22.27%
3Y Avg
-29.75%
5Y Avg
-35.86%
Market Cap
$491.55M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$547.86M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$487.30M
Return on Assets (ROA)
-8.14%
TTM Avg
-30.20%
3Y Avg
-72.84%
5Y Avg
-64.85%
Market Cap
$481.33M
Return on Assets (ROA)
1.38%
TTM Avg
-14.74%
3Y Avg
-19.98%
5Y Avg
-18.10%
Market Cap
$478.54M
Return on Assets (ROA)
-22.99%
TTM Avg
-20.77%
3Y Avg
-18.00%
5Y Avg
-22.63%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Altimmune, Inc. (ALT) | $519.25M | -17.40% | -49.85% | -45.66% | -41.17% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -89.18% | -100.15% | -92.96% | -79.13% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -30.08% | -46.42% | -46.30% | -37.15% |
| Evolus, Inc. (EOLS)vs › | $491.93M | -13.84% | -22.27% | -29.75% | -35.86% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -3.84% | -6.38% | -6.57% | -4.38% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.39% | -16.14% | -90.03% | -84.55% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | -8.14% | -30.20% | -72.84% | -64.85% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 1.38% | -14.74% | -19.98% | -18.10% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -22.99% | -20.77% | -18.00% | -22.63% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -20.89% | 7.49% | -5.84% | -12.60% |
ROA
-17.4%
ROE
-19.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -31.47% |
| 2024-12-31 | -68.24% |
| 2023-12-31 | -41.99% |
| 2022-12-31 | -40.94% |
| 2021-12-31 | -44.36% |
| 2020-12-31 | -20.01% |
| 2019-12-31 | -37.96% |
| 2018-12-31 | -71.54% |
| 2017-12-31 | -73.66% |
| 2016-12-31 | 86.26% |
| 2015-12-31 | -17.32% |
| 2014-12-31 | -45.30% |
| 2013-12-31 | -68.37% |
| 2012-12-31 | -21.64% |
| 2011-12-31 | -16.65% |
| 2010-12-31 | -128.13% |
| 2009-12-31 | -94.76% |
| 2008-12-31 | -64.58% |
| 2007-12-31 | -20.40% |
| 2006-12-31 | 1.42% |
| 2005-12-31 | 0.40% |
